Cytocompatible hydrogel derived from dextrin and Poly(N-Vinyl acetamide) toward controlled antimicrobial release

Abstract

The work aims to develop a biopolymer-dextrin-based three-dimensional crosslinked hydrophilic material for antimicrobial delivery. The copolymer (Dxt-PNVA) has been prepared by in-situ grafting of poly(N-vinylacetamide), followed by cross-linking with N,N'-methylenebisacrylamide with dextrin. By varying the concentrations of the reactants, an optimized copolymer (Dxt-PNVA 5) with the lowest % of crosslinking has been chosen for biomedical applications. The copolymeric gel has been characterized in detail using various techniques, followed by its cytocompatibility study using HeLa Cell lines that confirm the cytocompatible nature of the material. Copolymeric gel is a suitable material for the effective release of two antimicrobials (amoxicillin trihydrate and ornidazole) from tablet formulation for a prolonged period of 24 h. The obtained data demonstrates that the cytocompatible hydrogel has the potential characteristics of a daily dose administration for amoxicillin trihydrate and ornidazole.

Graphical Abstract

Keywords:

• Biopolymer
• crosslinking
• cytocompatible
• dextrin
• drug delivery

Supplementary material

Brief description of characterization, swelling study, tablets preparation, rheology study, drug release kinetics and mechanism-related equations, and calculation of %of cross-linking; Synthesis details of the Dxt-PNVA hydrogelator (Table S1); FTIR spectrum of Dxt-PNVA 5 hydrogelator (Figure S1); FTIR spectral data of Dxt-PNVA 5 hydrogelator (Table S2); ¹H NMR spectrum of Dxt-PNVA used to determine % of crosslinking (Figure S2); EDAX spectrum of Dxt-PNVA 5 hydrogelator (Figure S3); Swelling study plot (Figure S4); Swelling ratio per time (SRT) of Dxt-PNVA hydrogelator (Figure S5); Ornidazole release date fitted in mathematical models (Figure S6); Amoxicillin trihydrate release date fitted in different kinetics and mechanism models (Figure S7); Fitted data from Figures S5 and S6 (Table S3); FTIR spectra of drugs loaded tablets (Figure S8); FTIR data of tablets (Table S4).

Acknowledgments

D.D acknowledged the University Grants Commission (Ref. No. 19-06/2011 (i) EU-IV; Sr. No. 2061110303, Dated: 30.11.2011), New Delhi, India for receiving financial support through the NET-JRF Scheme.

Author contributions

D.D. conceptualization, synthesis, characterization, and writing; S.D. executed the cell study; S.P. edited and supervised the research work.

Disclosure statement

No potential conflict of interest was reported by the authors.

Additional information

Funding

D.D acknowledged the University Grants Commission (Ref. No. 19-06/2011 (i) EU-IV; Sr. No. 2061110303, Dated: 30.11.2011), New Delhi, India for receiving financial support through the NET-JRF Scheme.